ESMO2017 演題レポート Madrid, Spain 08 Sep - 12 Sep 2017

2017年9月8日~12日にスペイン・マドリードで開催された 2017年 欧州臨床腫瘍学会学術集会(ESMO 2017 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。


Special Session


Prospective pooled analysis of six phase III trials investigating duration of adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for patients with stage III colon cancer: Updated results of IDEA (International Duration Evaluation of Adjuvant Chemotherapy)

Axel Grothey, et al.


Efficacy of 3 versus 6 months of Oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: Results from phase III ACHIEVE trial as part of the international duration evaluation of adjuvant therapy (IDEA) collaboration

Takayuki Yoshino, et al.

Proffered Paper session


KEYNOTE-059: Efficacy and safety of Pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal cancer

Zev A. Wainberg, et al.


Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Julien Edeline, et al.


Analysis of serum biomarkers in patients from a phase 3 study of Lenvatinib vs. Sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Richard S, Finn, et al.


Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and Irinotecan plus Bevacizumab versus m FOLFOX6 or CapeOX plus Bevacizumab as first-line treatment for metastatic colorectal cancer

Yoshito Komatsu, et al.


mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): A randomized phase II trial of the AIO (AIO-KRK-0109)

Michael Geissler, et al.


Neoadjuvant FOLFOX4 versus FOLFOX4 plus Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicenter randomized controlled trial (PRODIGE 22)

Mehdi Karoui, et al.


Randomized phase III study of Fluoropyrimidine (FP) plus Bevacizumab (BEV) vs. FP plus Irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) - study

Dominik P. Modest, et al.


Pertuzumab (P) + Trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a phase III study (JACOB)

Josep Tabernero, et al.


A phase III study of Nivolumab in previously treated advanced gastric or gastroesophageal junction cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)

Narikazu Boku, et al.

Poster Discussion session


YOSEMITE: A 3 arm double-blind randomized phase 2 study of Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (Abraxane®) and Placebo (GAP) versus Gemcitabine, Abraxane® and either 1 or 2 truncated courses of Demcizumab

Antonio Cubillo, et al.


A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)

Takaki Yoshikawa, et al.

Poster Display session


Analysis of angiogenesis biomarkers for Ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase 3 study

Josep Tabernero, et al.


Interim safety and clinical activity of Nivolumab in combination with S-1/Capecitabine plus Oxaliplatin in patients with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction cancer: Part 1 study of ATTRACTION-04 (ONO-4538-37)

Yoon-Koo Kang, et al.